
Human Microbiome Market Report and Forecast 2025-2034
Description
The global human microbiome market size was valued at USD 591.63 Million in 2024, driven by the increasing the rising technical advancements in diagnostic tools across the globe. The market size is anticipated to grow at a CAGR of 23.00% during the forecast period of 2025-2034 to achieve a value of USD 4689.23 Million by 2034.
Human Microbiome: Introduction
Human microbiome refers to the vast collection of microorganisms that reside in and on the human body, including bacteria, viruses, fungi, and other microbes. The collection of all microorganisms found on or in human tissues and biofluids, along with corresponding anatomical locations, include the skin, mammary glands, seminal fluid, uterus, ovarian follicles, lung, saliva, oral mucosa, conjunctiva, biliary tract, and gastrointestinal tract, among others.
Global Human Microbiome Market Analysis
The study of the human microbiome has gained significant attention in recent years due to its potential impact on human health and disease. The market encompasses various products, services, and research efforts, aimed at understanding and harnessing the potential of the microbiome. The increase in research and development activities that are focused on exploring the role of the human microbiome in various aspects of health, including digestion, immunity, metabolism, and disease development, has been contributing to the human microbiome market growth.
Additionally, microbiome-based therapies are being explored for various conditions, including gastrointestinal disorders, immune-related diseases, and metabolic disorders, owing to the growth of the market. Companies are capitalizing on the growing consumer interest in improving health and well-being through microbiome-focused products. The human microbiome market development is also propelled by the increasing collaborations and partnerships between academic institutions, pharmaceutical companies, biotechnology firms, and diagnostic companies.
Global Human Microbiome Market Segmentations
The EMR’s report titled “Human Microbiome Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Market Breakup by Product Type
The market for human microbiome is expanding significantly and is anticipated to continue doing so as a result of growing knowledge of the intricate relationships between the microbiome and human health. Due to the characterization, microbiome functioning has advanced scientific knowledge and allowed for the discovery of novel therapeutic targets, diagnostic indicators, and therapies.
The global human microbiome market expansion is being driven by the rising technical advancements in diagnostic tools and the rising awareness of illness diagnosis. Academic and research organizations, biotechnology and pharmaceutical firms, providers of diagnostic and sequencing equipment, and probiotic and prebiotic producers are some of the major stakeholders in the market for the human microbiome. The increased emphasis on preventative care is anticipated to raise the need for personalized medicines and treatments, along with the diagnostics for infectious diseases, both of which are directly influencing the market growth. These businesses engage in product development, clinical trials, research and development, and commercialization activities. The expanding global market for human microbiomes is also responsible for the rising number of partnerships between academic institutions and biotechnology, pharmaceutical, and other businesses.
Global Human Microbiome Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Human Microbiome: Introduction
Human microbiome refers to the vast collection of microorganisms that reside in and on the human body, including bacteria, viruses, fungi, and other microbes. The collection of all microorganisms found on or in human tissues and biofluids, along with corresponding anatomical locations, include the skin, mammary glands, seminal fluid, uterus, ovarian follicles, lung, saliva, oral mucosa, conjunctiva, biliary tract, and gastrointestinal tract, among others.
Global Human Microbiome Market Analysis
The study of the human microbiome has gained significant attention in recent years due to its potential impact on human health and disease. The market encompasses various products, services, and research efforts, aimed at understanding and harnessing the potential of the microbiome. The increase in research and development activities that are focused on exploring the role of the human microbiome in various aspects of health, including digestion, immunity, metabolism, and disease development, has been contributing to the human microbiome market growth.
Additionally, microbiome-based therapies are being explored for various conditions, including gastrointestinal disorders, immune-related diseases, and metabolic disorders, owing to the growth of the market. Companies are capitalizing on the growing consumer interest in improving health and well-being through microbiome-focused products. The human microbiome market development is also propelled by the increasing collaborations and partnerships between academic institutions, pharmaceutical companies, biotechnology firms, and diagnostic companies.
Global Human Microbiome Market Segmentations
The EMR’s report titled “Human Microbiome Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Market Breakup by Product Type
- Probiotics
- Prebiotics
- Medical Foods
- Supplements
- Others
- Therapeutics
- Diagnostics
- Obesity
- Diabetes
- Autoimmune Disorder
- Metabolic and Gastrointestinal Disorders
- Cancer
- Other Disease
- Retail Pharmacies
- Online Pharmacies
- Supermarkets and Hypermarkets
- Others
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
The market for human microbiome is expanding significantly and is anticipated to continue doing so as a result of growing knowledge of the intricate relationships between the microbiome and human health. Due to the characterization, microbiome functioning has advanced scientific knowledge and allowed for the discovery of novel therapeutic targets, diagnostic indicators, and therapies.
The global human microbiome market expansion is being driven by the rising technical advancements in diagnostic tools and the rising awareness of illness diagnosis. Academic and research organizations, biotechnology and pharmaceutical firms, providers of diagnostic and sequencing equipment, and probiotic and prebiotic producers are some of the major stakeholders in the market for the human microbiome. The increased emphasis on preventative care is anticipated to raise the need for personalized medicines and treatments, along with the diagnostics for infectious diseases, both of which are directly influencing the market growth. These businesses engage in product development, clinical trials, research and development, and commercialization activities. The expanding global market for human microbiomes is also responsible for the rising number of partnerships between academic institutions and biotechnology, pharmaceutical, and other businesses.
Global Human Microbiome Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- ENTEROME
- Yakult
- DuPont
- Metabiomics Corporation
- ViThera Pharmaceuticals, Inc.
- Second Genome Inc.
- MICROBIOME THERAPEUTICS LLC
- Vedanta Biosciences, Inc.
- Osel, Inc.
- Merck Sharp & Dohme Corp
- Seres Therapeutics
- Synthetic Biologics, Inc.
- 4D pharma plc
Table of Contents
350 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Global Human Microbiome Market Overview
- 3.1 Global Human Microbiome Market Historical Value (2018-2024)
- 3.2 Global Human Microbiome Market Forecast Value (2025-2034)
- 4 Global Human Microbiome Market Landscape
- 4.1 Global Human Microbiome Developers Landscape
- 4.1.1 Analysis by Year of Establishment
- 4.1.2 Analysis by Company Size
- 4.1.3 Analysis by Region
- 4.2 Global Human Microbiome Product Landscape
- 4.2.1 Analysis by Product Type
- 4.2.2 Analysis by Application
- 4.2.3 Analysis by Disease Type
- 4.2.4 Analysis by Distribution Channel
- 5 Global Human Microbiome Market Dynamics
- 5.1 Market Drivers and Constraints
- 5.2 SWOT Analysis
- 5.3 Porter’s Five Forces Model
- 5.4 Key Demand Indicators
- 5.5 Key Price Indicators
- 5.6 Industry Events, Initiatives, and Trends
- 5.7 Value Chain Analysis
- 6 Global Human Microbiome Market Segmentation
- 6.1 Global Human Microbiome Market by Product Type
- 6.1.1 Market Overview
- 6.1.2 Probiotics
- 6.1.3 Prebiotics
- 6.1.4 Medical Foods
- 6.1.5 Supplements
- 6.1.6 Others
- 6.2 Global Human Microbiome Market by Application
- 6.2.1 Market Overview
- 6.2.2 Therapeutics
- 6.2.3 Diagnostics
- 6.3 Global Human Microbiome Market by Disease Type
- 6.3.1 Market Overview
- 6.3.2 Obesity
- 6.3.3 Diabetes
- 6.3.4 Autoimmune Disorder
- 6.3.5 Metabolic and Gastrointestinal Disorders
- 6.3.6 Cancer
- 6.3.7 Other Disease
- 6.4 Global Human Microbiome Market by Distribution Channel
- 6.4.1 Market Overview
- 6.4.2 Retail Pharmacies
- 6.4.3 Online Pharmacies
- 6.4.4 Supermarkets and Hypermarkets
- 6.4.5 Others
- 6.5 Global Human Microbiome Market by Region
- 6.5.1 Market Overview
- 6.5.2 North America
- 6.5.3 Europe
- 6.5.4 Asia Pacific
- 6.5.5 Latin America
- 6.5.6 Middle East and Africa
- 7 North America Human Microbiome Market
- 7.1 Market Share by Country
- 7.2 United States of America
- 7.3 Canada
- 8 Europe Human Microbiome Market
- 8.1 Market Share by Country
- 8.2 United Kingdom
- 8.3 Germany
- 8.4 France
- 8.5 Italy
- 8.6 Others
- 9 Asia Pacific Human Microbiome Market
- 9.1 Market Share by Country
- 9.2 China
- 9.3 Japan
- 9.4 India
- 9.5 ASEAN
- 9.6 Australia
- 9.7 Others
- 10 Latin America Human Microbiome Market
- 10.1 Market Share by Country
- 10.2 Brazil
- 10.3 Argentina
- 10.4 Mexico
- 10.5 Others
- 11 Middle East and Africa Human Microbiome Market
- 11.1 Market Share by Country
- 11.2 Saudi Arabia
- 11.3 United Arab Emirates
- 11.4 Nigeria
- 11.5 South Africa
- 11.6 Others
- 12 Patent Analysis
- 12.1 Analysis by Type of Patent
- 12.2 Analysis by Publication year
- 12.3 Analysis by Issuing Authority
- 12.4 Analysis by Patent Age
- 12.5 Analysis by CPC Analysis
- 12.6 Analysis by Patent Valuation
- 12.7 Analysis by Key Players
- 13 Grants Analysis
- 13.1 Analysis by year
- 13.2 Analysis by Amount Awarded
- 13.3 Analysis by Issuing Authority
- 13.4 Analysis by Grant Application
- 13.5 Analysis by Funding Institute
- 13.6 Analysis by NIH Departments
- 13.7 Analysis by Recipient Organization
- 14 Funding Analysis
- 14.1 Analysis by Funding Instances
- 14.2 Analysis by Type of Funding
- 14.3 Analysis by Funding Amount
- 14.4 Analysis by Leading Players
- 14.5 Analysis by Leading Investors
- 14.6 Analysis by Geography
- 15 Partnership and Collaborations Analysis
- 15.1 Analysis by Partnership Instances
- 15.2 Analysis by Type of Partnership
- 15.3 Analysis by Leading Players
- 15.4 Analysis by Geography
- 16 Regulatory Framework
- 16.1 Regulatory Overview
- 16.1.1 US FDA
- 16.1.2 EU EMA
- 16.1.3 INDIA CDSCO
- 16.1.4 JAPAN PMDA
- 16.1.5 Others
- 17 Supplier Landscape
- 17.1 ENTEROME
- 17.1.1 Financial Analysis
- 17.1.2 Product Portfolio
- 17.1.3 Demographic Reach and Achievements
- 17.1.4 Mergers and Acquisitions
- 17.1.5 Certifications
- 17.2 Yakult
- 17.2.1 Financial Analysis
- 17.2.2 Product Portfolio
- 17.2.3 Demographic Reach and Achievements
- 17.2.4 Mergers and Acquisitions
- 17.2.5 Certifications
- 17.3 DuPont
- 17.3.1 Financial Analysis
- 17.3.2 Product Portfolio
- 17.3.3 Demographic Reach and Achievements
- 17.3.4 Mergers and Acquisitions
- 17.3.5 Certifications
- 17.4 Metabiomics Corporation
- 17.4.1 Financial Analysis
- 17.4.2 Financial Portfolio
- 17.4.3 Demographic Reach and Achievements
- 17.4.4 Mergers and Acquisitions
- 17.4.5 Certifications
- 17.5 ViThera Pharmaceuticals, Inc.
- 17.5.1 Financial Analysis
- 17.5.2 Product Portfolio
- 17.5.3 Demographic Reach and Achievements
- 17.5.4 Mergers and Acquisitions
- 17.5.5 Certifications
- 17.6 Second Genome Inc.
- 17.6.1 Financial Analysis
- 17.6.2 Product Portfolio
- 17.6.3 Demographic Reach and Achievements
- 17.6.4 Mergers and Acquisitions
- 17.6.5 Certifications
- 17.7 MICROBIOME THERAPEUTICS LLC
- 17.7.1 Financial Analysis
- 17.7.2 Product Portfolio
- 17.7.3 Demographic Reach and Achievements
- 17.7.4 Mergers and Acquisitions
- 17.7.5 Certifications
- 17.8 Vedanta Biosciences, Inc.
- 17.8.1 Financial Analysis
- 17.8.2 Product Portfolio
- 17.8.3 Demographic Reach and Achievements
- 17.8.4 Mergers and Acquisitions
- 17.8.5 Certifications
- 17.9 Osel, Inc.
- 17.9.1 Financial Analysis
- 17.9.2 Product Portfolio
- 17.9.3 Demographic Reach and Achievements
- 17.9.4 Mergers and Acquisitions
- 17.9.5 Certifications
- 17.10 Merck Sharp & Dohme Corp
- 17.10.1 Financial Analysis
- 17.10.2 Product Portfolio
- 17.10.3 Demographic Reach and Achievements
- 17.10.4 Mergers and Acquisitions
- 17.10.5 Certifications
- 17.11 Seres Therapeutics
- 17.11.1 Financial Analysis
- 17.11.2 Product Portfolio
- 17.11.3 Demographic Reach and Achievements
- 17.11.4 Mergers and Acquisitions
- 17.11.5 Certifications
- 17.12 Synthetic Biologics, Inc.
- 17.12.1 Financial Analysis
- 17.12.2 Product Portfolio
- 17.12.3 Demographic Reach and Achievements
- 17.12.4 Mergers and Acquisitions
- 17.12.5 Certifications
- 17.13 4D pharma plc
- 17.13.1 Financial Analysis
- 17.13.2 Product Portfolio
- 17.13.3 Demographic Reach and Achievements
- 17.13.4 Mergers and Acquisitions
- 17.13.5 Certifications
- 18 Global Human Microbiome Market - Distribution Model (Additional Insight)
- 18.1 Overview
- 18.2 Potential Distributors
- 18.3 Key Parameters for Distribution Partner Assessment
- 19 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 20 Company Competitiveness Analysis (Additional Insight)
- 20.1 Very Small Companies
- 20.2 Small Companies
- 20.3 Mid-Sized Companies
- 20.4 Large Companies
- 20.5 Very Large Companies
- 21 Payment Methods (Additional Insight)
- 21.1 Government Funded
- 21.2 Private Insurance
- 21.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.